Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2017

Schedule Of Cost And Fair Value Of Marketable Securities


		September 30, 2017
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Commercial Paper	$	3,230,566	$	-	$	(1,983)	$	3,228,583
Corporate Bonds		11,760,745		142		(12,124)		11,748,763
Total Marketable Securities	$	14,991,311	$	142	$	(14,107)	$	14,977,346

		December 31, 2016
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Certificates of Deposit	$	720,000	$	197	$	-	$	720,197
Commercial Paper		3,987,424		-		(1,684)		3,985,740
Corporate Bonds		4,035,805		-		(4,635)		4,031,170
Total Marketable Securities	$	8,743,229	$	197	$	(6,319)	$	8,737,107

Schedule Of Cost And Fair Value By Contractual Maturity


Maturity	Cost Basis		Fair Value
Less than 1 year	$	11,963,973	$	11,955,906
1 to 5 years		3,027,338		3,021,440
Total Marketable Securities	$	14,991,311	$	14,977,346

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details